HealthQuill Gene Editing
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More
Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases as well as traumatic injury.
Uncategorized

‘Mailman’ gene-editing tool carries molecule to exact ‘zip code’

HQ Team May 24, 2025: Stanford University researchers have developed a gene-editing technology, which they hope will lead to treatments for neurological diseases.

Read More
Sonia Vallabh, a graduate of Harvard Law School and her husband  Eric Minikel, who holds a planning degree from MIT, re-engineered their careers to do research into prion disease when she was diagnosed with the disorder. Now their research may lead to a treatment if not a cure in the not-too-distant future, according to a statement from Harvard.
Uncategorized

Patient-scientist behind new gene-editing tool for prion disease

HQ Team April 10, 2025:  Sonia Vallabh, a graduate of Harvard Law School and her husband  Eric Minikel, who holds a planning degree.

Read More
United Therapeutics Corporation, a public benefit corporation, got approval from US regulators to start a clinical trial for organ transplantation from genetically modified pigs to treat kidney disease.
Drugs Health Medical

US regulator approves pig organ transplant trial to treat kidney disease 

United Therapeutics Corporation, a public benefit corporation, got approval from US regulators to start a clinical trial for organ transplantation from genetically modified.

Read More
Global researchers, led by Australia’s Macquarie University, in a bid to re-engineer life in a laboratory, have completed the world’s first synthetic yeast genome following more than a decade of work.
Drugs Health Medical

Global researchers complete world’s first synthetic yeast genome project

Global researchers, led by Australia’s Macquarie University, in a bid to re-engineer life in a laboratory, have completed the world’s first synthetic yeast.

Read More
A clinical-stage US gene-editing company, Precision BioSciences, got approval from the Eastern European country of Moldova to start an in vivo human trial of a therapy to treat chronic hepatitis B.
Drugs Health Pharma

Moldova green lights Precision BioSciences human trial for HBV

A clinical-stage US gene-editing company, Precision BioSciences, got approval from the Eastern European country of Moldova to start an in vivo human trial.

Read More
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Drugs Health Pharma

Roche to pay $42 million to Ascidian to make RNA exon editing drugs

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

Read More
The USFDA has approved two treatments for sickle cell disease, one of them the first in the US based on gene-editing technology.
Drugs Health Pharma

US drug regulator approves two treatments for sickle cell disease 

HQ Team December 8, 2023: The USFDA has approved two treatments for sickle cell disease, one of them the first in the US.

Read More
The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory at the Milner Therapeutics Institute
Drugs Health Pharma

Cambridge Univ, AstraZeneca, MRC to set up genomics laboratory

HQ Team November 29, 2023: The University of Cambridge announced a partnership with AstraZeneca and the Medical Research Council to set up a functional genomics laboratory.

Read More